

*Claims*

1. Use of a composition comprising, in admixture or separately:

(a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt;

5 (b) a second active ingredient which is budesonide; and

a molar ratio of the first active ingredient to the second active ingredient of from 1:2500 to 12:1,

10 in the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease.

2. Use according to claim 1, wherein the composition comprises one or more pharmaceutically acceptable additives, diluents and/or carriers.

15 3. Use of a kit containing:

(i) a vessel containing a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt;

(ii) a vessel containing a second active ingredient which is budesonide;

(iii) a molar ratio of the first active ingredient to the second active ingredient of from 1:2500 to 12:1; and

20 (iv) instructions for the simultaneous, sequential or separate administration of the first and second active ingredients to a patient in need thereof;

in the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease.

25 4. Use according to claim 3, wherein the first and/or second active ingredient is used in admixture with one or more pharmaceutically acceptable additives, diluents and/or carriers.

5. Use according to any one of the preceding claims, wherein the first active ingredient is 30 formoterol fumarate dihydrate.

6. Use according to any one of the preceding claims, wherein the molar ratio of the first active ingredient to the second active ingredient is from 1:555 to 2:1, preferably from 1:70 to 1:4.

5    7. Use of formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt in the manufacture of a composition as defined in claim 1 or 2 or a kit as defined in claim 3 or 4 for use in the treatment of chronic obstructive pulmonary disease.

10    8. Use of budesonide in the manufacture of a composition as defined in claim 1 or 2 or a kit as defined in claim 3 or 4 for use in the treatment of chronic obstructive pulmonary disease.

15    9. A method for the treatment of a patient suffering from chronic obstructive pulmonary disease which method comprises administering to the patient via inhalation, simultaneously, sequentially or separately, a therapeutically effective amount of (i) a dose of a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt; and (ii) a second active ingredient which is budesonide, and wherein the molar ratio of the first active ingredient to the second active ingredient is from 1:2500 to 12:1.

20    10. A method for the treatment of a patient suffering from chronic obstructive pulmonary disease which method comprises administering to the patient via inhalation a therapeutically effective amount of a composition as defined in claim 1 or 2.